Full-Time
Business Development Director
RCA Insights
Posted on 7/2/2026
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Texas, USA
Remote
Bachelor's, Master's, MBA
 Business & Strategy (1) |
|---|
Get referred to Cencora
See people who can refer or advise you
- Bachelor’s degree required; advanced degree (MBA/MPH/MS) a plus.
- 8+ years in business development/strategic partnerships/commercial roles in life sciences, healthcare, research services, or data/analytics.
- Demonstrated experience with manufacturers/pharma partners, including shaping and supporting partnership or deal structures.
- Strong clinical aptitude and ability to engage credibly with medical and scientific stakeholders.
- Ability to translate complex clinical/research/data concepts into compelling commercial value.
- Proven cross-functional leadership and project management across Research, Analytics, Product, and Legal/Compliance.
- Develop and grow manufacturer partnerships across pharma, biotech, and related sectors.
- Own opportunities end-to-end: discovery, solution shaping, proposals, and deal execution.
- Represent RCA Insights in executive-level discussions with commercial, medical, and research stakeholders.
- Support deal structuring and negotiation with BD, Legal, and executive leadership.
- Translate RCA manufacturing, research, and clinical data into commercially relevant insights.
- Partner with Product, Analytics, and Research to package insights into differentiated offerings, including scalable product opportunities.
- Apply clinical credibility to ensure messaging resonates with medical and scientific audiences.
- Ensure all partnerships and projects comply with regulatory requirements and RCA Research protocols.
- Support development and submission of study protocols, regulatory documents, and sponsor deliverables.
- Partner with legal and compliance teams to maintain appropriate agreements, documentation, and audit readiness.
- Contribute to regulatory submissions (e.g., protocols, study documentation, reporting requirements).
- Quarterback deals across research, analytics, clinical leaders, legal/compliance, and delivery teams.
- Drive scope, timelines, and commitments with strong project management discipline.
- Oversee transition from deal close through operational execution, ensuring alignment on scope, timelines, and deliverables.
- Act as a liaison between sponsors, RCA practices, and internal teams to ensure successful delivery.
- Monitor project execution and proactively resolve issues across stakeholders.
- Coordinate across RCA Insights, RCA Research, and enterprise teams to ensure aligned execution.
- Establish and document workflows, communication plans, and roles across stakeholders.
- Ensure clarity of scope, deliverables, and timelines across internal and external partners.
- Support financial tracking, including project-level performance, invoicing coordination, and reporting.
- Partner with finance teams on revenue tracking, contract execution, and account management activities.
- Represent RCA Insights in internal leadership forums and cross-functional committees
- Support preparation for executive meetings, sponsor presentations, and industry conferences.
- Participate in key industry events to strengthen partnerships and pipeline.
- Ensure accurate documentation and reporting across key workflows and systems.
- Real- world-evidence (RWE), clinical research services, data/analytics commercialization, clinical trial ecosystem familiarity, and experience in build-and-scale environments.
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Get referred to Cencora
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 5, 2026 results raised fiscal 2026 EPS guidance to $17.75-$17.95.
- July 31, 2026 credit facility expansion to $7 billion strengthens liquidity through 2031.
- Specialty medicine demand and GLP-1 volume lifted third-quarter revenue to $84.75 billion.
What critics are saying
- $4.2 billion opioid liability remains outstanding as of June 30, 2026.
- The 2024 Cencora data breach settlement keeps cybersecurity and trust damage visible through 2026.
- Specialty and GLP-1 concentration creates margin pressure if manufacturer pricing or mix shifts again.
What makes Cencora unique
- Cencora owns irreplaceable pharmaceutical distribution scale across U.S. Healthcare and International networks.
- February 2026 OneOncology deepens specialty oncology workflows and physician practice integration.
- Nucleus inventory tooling embeds Cencora inside specialty practices' medication and billing operations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Company News
Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.
Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.
CVS Health led health insurance providers in Q1, with revenues of $100.4 billion, up 6.2% year on year and beating analyst expectations by 6.3%. The company exceeded full-year EPS guidance estimates. The 12 health insurance provider stocks tracked reported strong Q1 results overall. Revenues beat consensus estimates by 1.4%, whilst next quarter's guidance was in line. Share prices rose 37.4% on average following the earnings announcements. Cencora performed weakest amongst peers, reporting revenues of $78.36 billion, up 3.8% year on year. This fell short of analyst expectations by 3.9%. The stock has remained flat since reporting and currently trades at $303.53. The industry faces tailwinds from an ageing population and improved data analytics, but regulatory scrutiny on pricing and medical cost inflation may impact margins.
Cencora has launched a multi-site pilot of its upgraded Nucleus inventory management solution for specialty physician practices, aiming to improve medication workflow efficiency and inventory visibility. The company has also appointed Samantha Hammock, formerly of Verizon, as chief human resources officer, succeeding Silvana Battaglia. The company's stock trades at $286.13, approximately 18% below the $351 analyst consensus target. Cencora has posted mixed returns, gaining 5.3% over the past week and 6.2% over the past month, whilst declining 15.6% year to date. A key risk flagged by analysts is that debt is not well covered by operating cash flow. Investors will monitor adoption feedback from pilot sites and how the leadership changes affect the company's specialty care operations.
Cencora has launched a multi-site pilot of its enhanced Nucleus inventory management solution across more than 20 specialty physician practice sites. The updated platform combines redesigned physical infrastructure with improved software to help practices manage complex medication workflows more efficiently. Developed with input from customer advisory boards and care providers, the enhanced solution features a modular cabinet design, larger integrated touchscreen, built-in workspace improvements and a unified interface designed to reduce training time. The system provides real-time inventory tracking, demand forecasting and automated billing support. The pilot will evaluate system performance across different practice settings. Pending outcomes, Cencora expects to begin scaling production and installation later this year, with expanded availability planned for existing and new customers.